A postmenopausal woman with ER+/PR+ HER2− breast cancer is on adjuvant letrozole (aromatase inhibitor) and develops joint pain and bone loss. Bisphosphonate therapy is initiated. According to current ASCO/St Gallen guidelines, the additional benefit of bisphosphonates (specifically zoledronic acid) in adjuvant breast cancer treatment is:

• A Reduced local recurrence rate in all breast cancer subtypes
• B Improved disease-free survival by reducing bone metastases in postmenopausal women ✓
• C Reduced visceral metastasis rate regardless of menopausal status
• D Prevention of brain metastases in HER2+ disease

Explanation

Multiple meta-analyses (EBCTCG 2015) confirm that adjuvant bisphosphonates (zoledronic acid or clodronate) significantly reduce bone metastases and improve disease-free survival specifically in postmenopausal women (natural or induced). The benefit is not clearly seen in premenopausal women with estrogen levels intact. This effect is independent of ER status and does not prevent visceral or brain metastases.

Reference: Bailey & Love's Short Practice of Surgery, 27th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.